Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study

PURPOSE: The use of growth factors adds considerable expense and some toxicity to adjuvant breast cancer chemotherapy. We tested the feasibility and safety of omitting routine peg-filgrastim use during the paclitaxel portion of the dose-dense doxorubicin-cyclophosphamide–paclitaxel regimen. PATIENTS...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Clin Oncol
Κύριοι συγγραφείς: Vaz-Luis, Ines, Barroso-Sousa, Romualdo, Di Meglio, Antonio, Hu, Jiani, Rees, Rebecca, Sinclair, Natalie, Milisits, Lindsey, Leone, Jose Pablo, Constantine, Michael, Faggen, Meredith, Briccetti, Frederick, Block, Caroline, O'Neil, Kelly, Partridge, Ann, Burstein, Harold, Waks, Adrienne G., Trippa, Lorenzo, Tolaney, Sara M., Hassett, Michael, Winer, Eric P., Lin, Nancy U.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2020
Θέματα:
ORIGINAL REPORTS
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7367545/
https://ncbi.nlm.nih.gov/pubmed/32330102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02484
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια